3,320
edits
Changes
Trimethoprim - Dihydrofolate Reductase Inhibitors (view source)
Revision as of 12:52, 24 October 2008
, 12:52, 24 October 2008→Pharmacokinetic Considerations
==Pharmacokinetic Considerations==
==Pharmacokinetic Considerations==
Dihydrofolate reductase inhibitors: Lipophilic weak bases.
• Orally active.
• Widely distributed throughout the body, ion trapped in acidic fluids.
• Cleared by hepatic metabolism – rate varies with species and individual drug (trimethoprim rapidly metabolised by most veterinary species).
==Side Effects and Contraindications==
==Side Effects and Contraindications==